Detail akcie ADOCIA online

Business Summary: Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Adocia SA revenues increased from EUR0K to EUR1M. Net loss increased 4% to EUR9.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Share-based payments increase from EUR152K to EUR1.3M (expense), Payroll expense increase of 7% to EUR4.6M (expense), Research tax credit decrease of 19% to EUR1.2M (income).